Port Delivery System Therapies in Retinal Vascular Diseases

In “Port Delivery System Therapies in Retinal Vascular Diseases,” our panel explores the role of the ranibizumab port delivery system (PDS) in the management of retinal vascular diseases and discusses how the reintroduction of this surgical approach is influencing treatment strategies in clinical practice. The panelists review the durability benefits associated with the PDS while also examining the practical, safety, and access considerations that may limit broader adoption.

Throughout the discussion, the expert faculty highlight long-term clinical trial and real-world data demonstrating substantial durability with the ranibizumab PDS, including sustained disease control and high patient satisfaction among many individuals previously treated with intravitreal injections. The panel discusses how refill-exchange procedures may improve patient comfort and reduce injection burden for select patients requiring frequent anti-VEGF therapy. However, the expert faculty also emphasize that the PDS introduces surgical risks not typically encountered with standard intravitreal injections, including endophthalmitis, retinal detachment, implant complications, and vitreous hemorrhage.

The panel further explores how advances in second-generation anti-VEGF therapies with longer durability profiles may be changing the risk-benefit considerations surrounding the PDS. In addition, the expert faculty discuss how access barriers, surgical workflow considerations, and patient willingness to undergo an operative procedure continue to influence real-world utilization. Overall, the discussion underscores the importance of careful patient selection and individualized treatment planning when considering the ranibizumab PDS for long-term retinal vascular disease management.

Our next episode, “Managing Retinal Vascular Diseases in Clinical Practice,” explores how panelists approach treatment switching, interval extension, and patient counseling when managing suboptimal responses to anti-VEGF therapy. The expert faculty also discuss adjunctive treatment strategies, durability expectations, and how second-generation anti-VEGF agents are shaping long-term disease management decisions.